Loading...
•
Jun 30, 2024
United Therapeutics Q2 2024 Earnings Report
Reported a record revenue driven by continued traction for Tyvaso and strong fundamentals for other products.
Key Takeaways
United Therapeutics reported a 20% year-over-year increase in total revenues, reaching $714.9 million in the second quarter of 2024, compared to $596.5 million in the second quarter of 2023. The growth was primarily driven by Tyvaso, Remodulin, Orenitram and Unituxin.
Total revenues grew by 20% year-over-year to $714.9 million.
Net income increased by 7% to $278.1 million.
Tyvaso revenues increased by 25% to $398.2 million.
The company expects data from its innovative clinical pipeline next year.
United Therapeutics
United Therapeutics
United Therapeutics Revenue by Segment
United Therapeutics Revenue by Geographic Location
Revenue by Segment
Tyvaso DPI Revenue
CapyFin.comNebulized Tyvaso Revenue
CapyFin.comRemodulin Revenue
CapyFin.comOrenitram Revenue
CapyFin.comUnituxin Revenue
CapyFin.comAdcirca Revenue
CapyFin.comOther Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
The company anticipates near-term commercial growth and the progress of its organ manufacturing programs.
Positive Outlook
- Anticipated near-term commercial growth.
- Expected progress of organ manufacturing programs.
- Innovative clinical pipeline potential.
- Focus on unmet medical needs of patients.
- Development of novel pharmaceutical therapies.
Challenges Ahead
- Risks and uncertainties described in periodic reports.
- Potential differences between actual and anticipated results.
- Cautionary statements in periodic reports.
- Risk factors in SEC filings.
- No obligation to update or revise information.
Revenue & Expenses
Visualization of income flow from segment revenue to net income